Posts by: Isaura Santos

Isaura Santos

Isaura Santos graduated with a BS in Cell and Molecular Biology from Universidade Nova de Lisboa and a MA in Communication, Culture and Information Technologies from University Institute of Lisbon (ISCTE-IUL). Her professional interests include science communication, public awareness of science and communication of science through entertainment.

August 17, 2015August 17, 2015

Depression, Stress, Anxiety and Anger Linked With Higher Risk For Cardiovascular Disease In RA Patients

News

A recent study has showed that depressive symptoms such as anxiety, stress, anger and lack of social support in patients suffering with rheumatoid arthritis (RA) are connected to atherosclerosis, a condition characterized ... Read more

June 9, 2015June 9, 2015

“Creativity” Is Essential To Treat Difficult Rheumatoid Arthritis Symptoms, According To Specialist

News, rheumatoid arthritis

Rheumatologists need to “get creative” while treating rheumatoid arthritis, according to Dr. Daniel Furst, a Carl Pearson Professor of Medicine and director of the Rheumatology Clinical Research Center at the University of California ... Read more

June 8, 2015June 12, 2015

Bristol-Myers Squibb To Present Results On RA Therapy Orencia At EULAR 2015

News, rheumatoid arthritis

Bristol-Myers Squibb will present data from 14 abstracts pertaining to its rheumatoid arthritis therapy Orencia (abatacept) at the European League Against Rheumatism (EULAR) 2015 Annual Meeting. Rheumatoid arthritis is a systemic, chronic ... Read more

April 23, 2015April 24, 2015

Researchers Focus On Benefits & Risks Of Biosimilar Antibodies For RA

News, rheumatoid arthritis

The biosimilar market is emerging and biosimilar antibodies are now being developed in order to address treatment to conditions that are being treated by their original and biological therapy. There are very few biosimilars ... Read more

March 31, 2015March 31, 2015

Arthritis Foundation Supports Legislation To Ensure Access To Innovative Treatments For Rheumatoid Arthritis Patients

News

The Arthritis Foundation is supporting new bipartisan legislation recently introduced in the House of Representatives that will serve to address a concerning trend in the current health insurance market: moving vital medications into specific categories in ... Read more

March 30, 2015March 30, 2015

Cipher Pharmaceuticals Acquires Canadian Rights To New Rheumatoid Arthritis Treatment

News, rheumatoid arthritis

Cipher Pharmaceuticals Inc. recently announced that the company has secured the license to distribute CF101 in Canada. CF101 is a new chemical being advanced by Can-Fite Biopharma to address rheumatoid arthritis and moderate to severe plaque ... Read more

March 19, 2015March 19, 2015

Samsung Bioepis Announces MAA Submission for SB2, Biosimilar Of Remicade

News

Samsung Bioepis Co., Ltd., has recently announced its submission to the European Medicines Agency (EMA) concerning the Marketing Authorization Application (MAA) for SB2, a biosimilar candidate for Remicade (Infliximab). This is the second MAA for biosimilar candidates that Samsung ... Read more

March 10, 2015March 10, 2015

NIHR and Janssen To Study Why Rheumatoid Arthritis Biological Treatments Fail In A Third Of Patients

News

The National Institute for Health Research (NIHR) recently announced a partnership with Janssen to investigate why current rheumatoid arthritis biological treatments end up failing in about a third of the patients. ... Read more

March 9, 2015March 9, 2015

Rheumatologists Called To Stand Against Growing Health Insurance Denials

News, rheumatoid arthritis

UBM Medica US recently announced that the Rheumatology Network, which is an online community dedicated to rheumatologists, will be featuring a commentary encouraging rheumatologists to mobilize themselves, with the support of their patients, ... Read more

February 25, 2015February 25, 2015

Galapagos Reports Last Patient in DARWIN 1 RA Clinical Trials Has Completed 12 Weeks Of Treatment

News, rheumatoid arthritis

Galapagos NV is a clinical stage biotechnology company specialized in small molecule therapies that is developing medicines with novel mechanisms of action. The company has recently announced that the last patient in their DARWIN 1 trial treated with filgotinib has completed 12 weeks ... Read more